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Abstract 
Disorders or differences in sex development (DSD) comprise a heterogeneous group of 
conditions with an atypical sex development. For optimal diagnosis highly specialized laboratory 
analyses are required across European countries. Working group 3 of EU COST (European 
Cooperation in Science and Technology) Action BM 1303 “DSDnet” “Harmonisation of 	
Laboratory Assessment” has developed recommendations on laboratory assessment for DSD 

regarding the use of technologies and analytes to be investigated. This position paper on 
steroid hormone analysis in diagnosis and treatment of DSD was compiled by a group of 
specialists in DSD and/or hormonal analysis, either from participating European Countries or 
international partner countries. The topics discussed comprised analytical methods 
(immunoassay/mass spectrometry based methods), matrices (urine/serum/saliva) and 
harmonisation of laboratory tests. The following positions were agreed upon: Support of the 
appropriate use of immunoassay and mass spectrometry based methods for diagnosis and 
monitoring of DSD. Serum/plasma and urine are established matrices for analysis. Laboratories 
performing analyses for DSD need to operate within a quality framework and actively engage in 	
harmonisation processes so that results and their interpretation are the same irrespective of the 

laboratory they are performed in. Participation in activities of peer comparison such as sample 
exchange or when available subscribing to a relevant external quality assurance program 
should be achieved. The ultimate aim of the guidelines is the implementation of clinical 
standards for diagnosis and appropriate treatment of DSD to achieve the best outcome for 
patients, no matter where patients are investigated or managed.  
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1. Introduction 
Disorders or differences in sex development (DSD) comprise a heterogeneous group of 
conditions with an atypical sex development. Patients with DSD are complex and rare, and 
multi7disciplinary teams are needed for optimal diagnosis and management. Thus, highly 	
specialized laboratory analyses are required across European countries. COST (European 

Cooperation in Science and Technology) Action “DSDnet” forms a network bringing together 
different stakeholders and people interested in DSD, scientists, clinicians, as well as people with 
DSD (www.dsdnet.eu). Working group 3 “Harmonisation of Laboratory Assessment” of the 
COST action “DSDnet”, has developed recommendations on laboratory assessment for DSD 
regarding the use of technologies and analytes to be investigated. This important work will form 
the basis of future European reference Network for rare endocrine disorders. This position 
paper on steroid hormone analysis in diagnosis and treatment of DSD was compiled by a group 
of specialists in DSD and/or hormonal analysis, either from participating European Countries or 
international partner countries.  	
 

1.1 Relevance of Clinical Steroid Analysis 	
The Chicago consensus statement and recent literature regarding disorders of sex development 	
emphasizes the need for comprehensive diagnosis and treatment of DSD 175. Diagnosis of DSD 	
remains challenging for involved pediatricians, endocrinologists, geneticists, urologists and 	
other related disciplines, as even with novel approaches a specific molecular diagnosis is only 	
achieved in about 30750% of patients with 46,XY DSD 4. Thus, the diagnostic pathway in 	
patients with DSD requires close interlinking between the clinical, biochemical and genetic 	
diagnostic work7up. 	
Traditionally, hormonal analyses in blood or urine have been used as part of the first7line 		
diagnostic approach. In current practice, this is more frequently used in combination with 	

molecular genetic analyses. In addition to diagnostic data, biochemical analysis will provide 

additional functional information guiding further management, disease monitoring and explain 

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differences in phenotypic expression. However, this heavily depends on local and national 

diagnostic pathways and regional differences in accessibility to highly specialized analyses. 

There are significant differences in funding streams, clinical and laboratory resources as well as 

the interplay with research laboratories, resulting in a heterogeneous situation in Europe. In 

many countries, clinical endocrinology has increasingly become dominated by economic 

constraints. While hormone measurement has traditionally been a mainstay of clinical 

endocrinology, the absorption of hormone labs by centralized laboratory units is associated with 
	
the risk of loss of expertise in hormone test development, selection, and data interpretation. A 


Pan7European and ultimately a global approach should aim for a harmonisation of diagnostic 
pathways according to requirements achieving the correct diagnosis. 
The majority of 46,XX infants presenting with virilization of the external genitalia will have 
congenital adrenal hyperplasia (CAH). In such cases a quantification of multiple steroids in a 
steroid profile is very important in order to detect rare forms of steroid biosynthesis disorders. A 
recent report on exome sequencing exemplifies the significant benefit of next generation 
sequencing techniques for diagnosing 46,XY DSD 4. However, the paper indirectly illustrates the 
requirement of detailed clinical and comprehensive biochemical data for a holistic 
understanding of individual DSD cases.  	
Hormonal analysis 6 is not only important for initial diagnosis of DSD. It also remains a decisive 

corner stone for monitoring adequate hormone replacement in various conditions with the goal 
of avoiding adrenal crises, ensuring optimal development of growth, weight and puberty,  
supporting sexual function and optimizing quality of life in patients with DSD. It is of paramount 
importance that any meaningful hormone data interpretation in relation to DSD has to take into 
consideration the patient’s individual clinical picture and requires age7 and sex7 specific 
reference intervals due to the changing physiology of the developing child and young person 77
10.  
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1.2 Advantages of Clinical Steroid Analysis: 
Clinical steroid profiling remains an important first line approach to the diagnosis of DSD, as it 	
provides fast and comprehensive results and thus allows for a rapid differential diagnostic 

orientation. In cases of CAH it has a good phenotype7genotype correlation 11.  
 
1.3 Challenges of Clinical Steroid Analysis  
Over the course of recent years it has become increasingly difficult to recruit healthy volunteers 
in childhood and adolescence to establish normative reference data from a control cohort. This 
is mainly the result of ethical concerns and prevents the implementation of accurate age7 and 
sex7specific reference intervals. Soeborg et al. (2014) 10 emphasize that medical treatment, 
such as exogenous steroids, hepatic metabolism interacting agents, or liquorice containing 
sweets can influence steroid metabolism and may influence the interpretation of results 12. 	
Recent studies also describe an impact of nutritional status on steroid hormone concentrations 

13. This indicates that there is an ongoing need for establishing reference intervals.  However, 
through the harmonisation of laboratory tests there is the potential to develop common 
reference intervals. The work required to generate this data should be shared thus allowing 
results from different laboratories to be directly compared. 
 
 
2. Analytical Methods 
The main aim of clinical guidelines is to implement clinical standards for diagnosis and 
appropriate treatment in order to achieve the best outcome for patients, no matter where 	
patients are investigated or managed. Therefore all methods require appropriate validation to 

ensure they are fit for their intended clinical purpose 14. This includes the important peer 
comparison processes of sample exchange or, if available, participation in an external quality 
assurance scheme (EQA).   
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2.1 Immunoassay Methods 
The principle of all immunoassay7based methods is the binding of an antigen to an antibody. In 
the late 1970s, the radioligands were replaced with chemoluminescence, enzymatic or 
fluorescent ligands. In general, immunoassay7based methods for steroid measurements detect 
a tracer rather than directly the analyte. Most clinical biochemistry laboratories adopted these 
assays due to their low cost, simplicity, and fast turn7around times. Immunoassays are available 	
for various steroidal analytes as commercial kits on automated platforms. One advantage of RIA 

methods is the wide and extensive experience as these assays have been used for almost 50 
years in clinical routine and research laboratories. During this time, a considerable amount of 
data has been accumulated and numerous studies have enriched the field of endocrinology 15. 
For some analytes such as estradiol very sensitive techniques exist 16, 17. Thus, immunoassays 
can produce highly specific results, particularly in combination with preceding extraction and/or 
chromatography of the samples 18. Improved separation through extraction is particularly 
important for newborns, especially if born early, as the fetal adrenal zone which produces a 
different mix of steroids persists until at least the equivalent of term 19. 
However, numerous commercial assays, especially automated immunoassays, have recently 	
been shown to have impaired specificity due to cross7reactivity of the antibody and other 

unidentified interferences from the matrix 20, 21. Therefore, tests evaluated in serum/plasma from 
healthy adults do not necessarily produce reliable values in neonates or pregnant women 22 or 
when applied in different matrices such as saliva or urine. The rapid analysis time in many high 
throughput analytical platforms may also be observed at the expense of poorer sensitivity 
(detection limit). Furthermore, immunoassays can only measure one steroid per analysis. Thus, 
larger volumes of serum/plasma are required for analysis. This can be particularly challenging 
when measuring small7volume samples from newborns and infants. The use of radioactivity in 
RIAs requires special laboratory facilities and generates radioactive waste. The lack of 
standardization of immunoassays represents a major problem for the comparability of laboratory 	
results, and in many cases method specific reference intervals must be considered for 

interpretation. In the current European landscape, immunoassays are still commonly employed 
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
for steroid hormone analysis. However, in the light of future developments it can be expected 
that immunoassays will increasingly be replaced by mass spectrometry based methods. 
 
2.2 Mass Spectrometry Based Methods 
Mass spectrometry based steroid hormone assays are physico7chemical analytical techniques 
identifying the analyte by determining typical mass to charge ratios of the respective molecule 
or its typical fragments. In contrast to conventional isotopic and non7isotopic immunoassay 
techniques, mass spectrometry allows for higher specificity 23. Liquid chromatography linked 	
with tandem mass spectrometry (LC7MS/MS) enables targeted steroid hormone analysis of 

multiple analytes from a single sample 9, 10, 24727. Gas chromatography coupled with mass 	
spectrometry (GC7MS) allows for the simultaneous determination of steroid hormones and 	
metabolites within targeted as well as non7targeted approaches. 	
At first glance, mass spectrometry based methods may appear rather costly due to the price of 	
sophisticated instrumentation, maintenance of equipment and the need for qualified personal 	
operating the instruments. However, in comparison to other diagnostic procedures, such as 	
molecular genetics, imaging procedures (computed tomography, magnetic resonance imaging, 	
isotope7based imaging techniques) or multiple immunoassays, hormone profiling by mass 	
spectrometry is actually very cheap. The use of LC–MS/MS for steroid analysis is still 		
challenging. One of the main complicating factors in mass spectrometric steroid analysis is the 	

presence of isobaric interferences  caused by ions of identical mass to charge ratio and similar 

fragmentation patterns 28. Although steroid analysis by LC7MS/MS is becoming increasingly 

available for routine use, validation and quality control present important future challenges 29. 

Reference intervals are not widely available and in contrast to earlier anticipation these are 

considerably dependent on individual specific laboratory settings, such as sample work up 

and/or instrumentation. 

 

Position 1: Whilst mass spectrometry is purported to be a superior technique, it is not available 

for all hormones and is currently not a realistic analytical option in all regions of Europe.  Our 
	
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

position is therefore to support the appropriate use of both immunoassay and mass 


spectrometry based methods for the diagnosis and monitoring of DSD. It is essential that 
clinicians should also know the characteristics and limitations of analytical methods used! 
 
 
3. Analytical Matrices 
Blood (serum vs. plasma), urine, and saliva 30, 31 are the biomaterial (i.e. matrices) most 
commonly used for clinical steroid hormone analysis. Saliva is less broadly established and few 
studies on steroids analyzed in saliva exist for the differential diagnosis of DSD, and the working 
group does not have a stance for or against the inclusion of this matrix currently. It is 	
recommended that clinicians contact their laboratories in advance to follow their 

recommendations regarding appropriate type of sample as well as mode of shipment 32734.   
 
Position 2: Both, serum/plasma and urine, are established matrices for analysis for steroids and 
dependent on the specific DSD condition under consideration, analysis of steroids in either 
matrix may be appropriate.  
 
 
4. Harmonisation of Laboratory Tests  
Initiatives in laboratory medicine that support harmonisation stem from Europe and are now 	
being embraced globally.  Bias, imprecision and interferences can all lead to erroneous results.  

As such, method validation is fundamental in establishing the extent and acceptability of each of 
these studies for clinical diagnostic assays to ensure they operate within an accepted quality 
framework.  Whilst each of these validation parameters is important, minimization of bias is 
essential for harmonisation. 
Harmonisation and, where practical standardization with traceability, are enormous challenges 
35.  The process has been described in terms of five supporting pillars, these are aimed at 
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
establishing: 1) certified reference materials (CRM); 2) reference measurement procedures 
(RMP); 3) reference laboratories; 4) participation in an EQA program; and 5) reference intervals 
and decision limits 36. 	
In principle, full standardization with traceability should be achievable for all steroids as they are 

small compounds of defined molecular weight.  The Joint Committee for Traceability in 
Laboratory Medicine (JCTLM) was established in 2002 to support this process worldwide 
through the development of a database to recognize primary reference materials, methods and 
laboratories (www.bipm.org/jctlm. Accessed 19th June 2016).  This JCTLM database, which is 
hosted by the Bureau International of Weights and Measures (BIPM) [Sevres Cedex, France], 
currently lists some (e.g. serum cortisol, estradiol, progesterone and testosterone) but not all 
steroids important for the assessment of DSD (e.g. serum 177hydroxyprogesterone, 
androstenedione, cortisone and dihydrotestosterone). 
 	
Participation in an EQA program is generally recognised to be the central pillar as it provides 

the framework for objective comparison of the result obtained by many laboratories for the one 
sample 37, 38.  However, in order to proceed down this pathway for the harmonisation of 
laboratory assessment, we first need to establish a collaborative agreement on the analytes and 
their matrices that should be measured for the differential diagnosis of a DSD. Recently, a first 
EQA program for the harmonisation of serum dihydrotestosterone analysis has been launched 
39. 
 
Position 3: Laboratories should aim to participate in activities of peer comparison such as a 
sample exchange or preferably when available subscribe to a relevant external quality 	
assurance program.  

  
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5. Steroid Analysis in Conditions Associated with DSD 
 
5.1 46,XX DSD Conditions 
215hydroxylase deficiency. CAH due to 217hydroxylase deficiency (21OHD) is the most 
common cause of DSD in 46,XX individuals 40. Due to overproduction of androgens, 46,XX 
individuals usually present with ambiguous genitalia without palpable gonads. The condition is 
treated with glucocorticoids and if required mineralocorticoids. In serum/plasma, 177
hydroxyprogesterone and 217deoxycortisol with or without ACTH7stimulation 	
(adrenocorticotropic hormone) are the indicative diagnostic parameters for 21OHD. Usually, no 

ACTH stimulation is required in classic CAH.  Urinary steroid profile analysis, a non7invasive 
means, also allows for definitive diagnosis: 177hydroxypregnanolone, pregnanetriol and 
pregnanetriolone are the key diagnostic urinary metabolites 41. Steroid monitoring of 21OHD is 
performed by determination of the above mentioned hormones and their metabolites in either 
serum, plasma, urine or saliva 42. 
11β5hydroxylase deficiency, is characterized by elevated serum/plasma 117deoxycortisol and 
deoxycorticosterone. Individuals with 46,XX DSD suffering from 11β7hydroxylase deficiency 
also present with virilization of the external genitalia. The onset of hyporenaemic, hypokalaemic, 
hypertension is variable. The urinary steroid profile is dominated by elevated tetrahydro7117	
deoxycortisol 43. 

3β5Hydroxysteroiddehydrogenase deficiency (3βHSDD). This condition is clinically 
characterized by undermasculinisation in 46,XY individuals and virilization in 46,XX individuals 
44. The pathognomic hormonal pattern is characterized by elevation of 177hydroxypregnenolone, 
dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEAS) in 
serum/plasma and increased excretion rates of their corresponding urinary metabolites 
including androstenetriol. 
P450 oxidoreductase deficiency. This condition presents biochemically as combined 177
hydroxylase/lyase and 217hydroxylase deficiency. It is caused by a defect of the electron 
donating protein to microsomal cytochrome P450 type 2 enzymes. The typical presentation is a 	
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
child with ambiguous genitalia and Antley7Bixler7syndrome; however, a wide spectrum of clinical 

presentations has been described 45. 	
 	
5.2 46,XY5DSD5Conditions 	
Steroid Acute Regulatory Protein (StAR) deficiency and P450 side5chain cleavage 	
enzyme (P450scc) deficiency. StAR deficiency leads to lipoid CAH, whereas deficiency of 	
P450scc commonly leads to small adrenals. Both conditions present with similar clinical 	
appearance. Only a few patients might have a severe salt loss crisis in the first months of life. 	
The majority of 46,XY individuals, shows undervirilization or complete feminization. In 46,XX 	
patients no further clinical features might be present in the first months of life. Typically, 		
glucocorticoids, mineralocorticoids and sex steroids are all low to undetectable. Treatment with 	

glucocorticoids (e.g. hydrocortisone) and later with sex hormones should be monitored by 

determining the respective steroids 46. 

175hydroxylase/17,20 lyase deficiency. Typically, 177deoxygenated steroids, e.g. 

corticosterone, are elevated, while 177oxygenated steroids, such as cortisol and sex steroids, 

are markedly reduced or absent in serum/plasma. Urinary steroid profile analysis likewise 

reflects an increase in 177deoxygenated over 177oxygenated metabolites 47. Patients are 

clinically often glucocorticoid replete despite impaired cortisol synthesis as corticosterone 

excess with its glucocorticoid action is compensating for the lack of cortisol. The deficiency of 

sex hormone biosynthesis is causing DSD in these individuals. All affected individuals (46,XY 
	
and 46,XX) with complete deficiency classically fail to develop secondary sexual characteristics. 


Similar to 11β7hydroxylase deficiency, the onset of hyporenaemic, hypokalemic hypertension is 
highly variable.  
P450OR deficiency: see above 
3βHSDD: see above  
5α5reductase deficiency. Patients with mutations in the 5α7reductase type 2 gene usually 
show undermasculinisation at birth. Usually there is some degree of masculinisation at puberty 
due to increasing concentrations of testosterone. Diagnosis can be established using the ratio 
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
of testosterone to dihydrotestosterone in serum/plasma before and after hCG (human chorionic 
gonadotropin) stimulation 48, 49. The diagnosis can also be made by assessing the ratio between 	
5α7 and 5β7reduced steroids in the urinary steroid profile 50. 

17β5Hydroxysteroiddehydrogenase type 3 deficiency. Due to the lack of testosterone during 
male sex differentiation, 46,XY children are often born with almost female7appearing external 
genitalia 51. In serum/plasma, the ratio of androstenedione / testosterone after hCG stimulation 
is elevated. Urine steroid metabolomic profiling for this enzyme deficiency might not always be 
indicative for this gonadal enzyme defect.  
 
Position 4: Harmonisation of the primary analytes for analysis of specific DSD is required. We 
propose that laboratories measure the diagnostic key steroids mentioned as described above. 
 	
 

6. Conclusions  
Since DSD represents a very heterogeneous and highly complex group of conditions, the 
integration of clinical, biochemical and genetic diagnostic approaches is required. The 
knowledge of steroid hormone biosynthesis is vital in understanding the pathogenesis of the 
specific condition. Furthermore, monitoring strategies of these entities are to a great extent 
based on biochemical parameters. Therefore, only most reliable methods are required.  To 
achieve this aim, laboratories performing analyses for DSD need to operate within a quality 
framework and actively engage in harmonisation processes so that results and their 
interpretation are the same irrespective of the laboratory they are performed in. 	
However, the situation with respect to access to analytical technologies is very heterogeneous 

within Europe. This is due to essential differences in health care systems, modes of payment, 
different economical coverage, and structure of biochemical services. This compromises the 
development of common strategies for Pan7European diagnosis and follow up in DSD. 
There is an urgent demand for establishing a network of highly specialized endocrine reference 
laboratories with expertise in DSD. These centers should have the required knowledge of 
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
analytical techniques, should have age7 and sex7specific reference intervals to provide 
normative data, and should provide experience with proper interpretation of values. It is 
essential to maintain and support existing laboratories with expertise in DSD. Therefore, the 
area of DSD also holds a deep political dimension. Interested parties are encouraged to contact 	
head of working group 3 for setting up a network of suitable reference laboratories. Investments 

to create and maintain such reference centers of expertise are vital to achieving a Pan7
European and ultimately a global landscape ensuring access to optimal laboratory assessment 
for DSD. 
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11. Figure legends 
Legend of figure 1 
Synthesis and metabolism of hormonal steroids. This figure illustrates the formation of the major 
hormone classes from cholesterol. Steroid names in conventional script are steroidhormones 
and precursors; those in italics are urinary metabolites of the aforementioned. The major 
transformative enzymes are in rectangular boxes, the cofactor (“facilitator”) enzymes in ovals. 
Mitochondrial CYP type I enzymes requiring electron transfer via adrenodoxin reductase (ADR) 
and adrenodoxin (Adx) CYP11A1, CYP11B1, CYP11B2, are marked with a labelled box 
ADR/Adx. Microsomal CYP type II enzymes receive electrons from P450 oxidoreductase 	
(POR), CYP17A1, CYP21A2, CYP19A1 and are marked by circled POR. The 17,207lyase 

reaction catalyzed by CYP17A1 requires in addition to POR also cytochrome b5 indicated by a 
circled b5. Similarly, hexose767phosphate dehydrogenase (H6PDH) is the cofactor7generating 
enzyme for 11β7HSD1 (HSD11B1). The asterisk (*) indicates the 117hydroxylation of 177
hydroxyprogesterone to 217deoxycortisol in 217hydroxylase deficiency. The conversion of 
androstenedione to testosterone is catalyzed by HSD17B3 in the gonad and AKR1C3 
(HSD17B5) in the adrenal. StAR, steroidogenic acute regulatory protein; CYP11A1, P450side7
chain cleavage enzyme; HSD3B2, 3β7hydroxysteroid dehydrogenase type 2; CYP17A1, 17α7
hydroxylase/17,207lyase; CYP21A2, 217hydroxylase; CYP11B1, 11β7hydroxylase; CYP11B2, 
aldosteronesynthase; HSD17B, 17β7hydroxysteroid dehydrogenase; HSD11B1, 11β7	
hydroxysteroid dehydrogenase type 1; HSD11B2, 11β7hydroxysteroid dehydrogenase type 2; 

SRD5A2, 5α7reductase type 2; SULT2A1, sulfotransferase 2A1; PAPSS2, 3´7
phosphoadenosine 5´7phosphosulfate synthase 2.  
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13. Figure 
Figure 1: Synthesis and metabolism of hormonal steroids 
 
14. Table 
Table 1: List of abbreviations 
 
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21OHD 21hydroxylase deficiency 
3βHSDD 3βhydroxysteroid dehydrogenase deficiency 
ACTH adrenocorticotropic hormone 
ADR adrenodoxin reductase 
Adx adrenodoxin 
BIPM Bureau International of Weights and Measures 
CAH congenital adrenal hyperplasia 
CRM certified reference materials 
CYP11A1 P450 sidechain cleavage enzyme (P450scc) 
CYP11B1 11βhydroxylase 
CYP11B2 aldosterone synthase 
CYP17A1 17αhydroxylase/17,20lyase 
CYP19A1 P450 aromatase 
CYP21A2 21hydroxylase 
DSD disorders or differences in sex development 
EQA external quality assurance 
EU COST European Cooperation in Science and Technology 
GCMS gas chromatographymass spectrometry 
H6PDH hexose6phosphate dehydrogenase 
hCG human chorionic gonadotropin 
HSD11B1 11βhydroxysteroid dehydrogenase type 1 
HSD11B2 11βhydroxysteroid dehydrogenase type 2 
HSD17B 17βhydroxysteroid dehydrogenase 
HSD3B2 3βhydroxysteroid dehydrogenase type 2 
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JCTLM Joint Committee for Traceability in Laboratory Medicine 
LCMS/MS liquid chromatographytandem mass spectrometry 
P450 cytochrome P450 
PAPSS2 3´phosphoadenosine 5´phosphosulfate synthase 2 
POR P450 oxidoreductase 
RIA radio immunoassay 
RMP reference measurement procedures 
SRD5A2 5αreductase type 2 
StAR steroidogenic acute regulatory protein 
SULT2A1 sulfotransferase 2A1 

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